Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

115.28 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,892
Open 115.28
Bid (Size) 114.99 (5)
Ask (Size) 115.05 (8)
Prev. Close 115.28
Today's Range 115.28 - 115.28
52wk Range 92.19 - 120.92
Shares Outstanding N/A
Dividend Yield 3.01%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga

Performance

YTD
+14.14%
+14.14%
1 Month
+3.46%
+3.46%
3 Month
+9.22%
+9.22%
6 Month
+16.44%
+16.44%
1 Year
+14.52%
+14.52%

More News

Read More
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Via Benzinga
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Via Benzinga
NYSE:NVS: good value for what you're paying.
Via Chartmill
Uncovering Dividend Opportunities with NYSE:NVS.
Via Chartmill
Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR.
Via Chartmill
Why NYSE:NVS is a Top Pick for Dividend Investors.
Via Chartmill
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Via Benzinga
Topics Economy
Exposures Interest Rates
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
Via Benzinga
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
From Lindy Biosciences
Via Business Wire
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Via Investor's Business Daily
Exposures Product Safety
Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
Via Benzinga
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Via The Motley Fool
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
Via Benzinga
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
Via Newsfile
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
Via Benzinga
Exposures Product Safety
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Via FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
From FN Media Group LLC
Via GlobeNewswire
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
Via Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.